Completed PHASE3 INTERVENTIONAL 2-arm NCT01234311

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Sponsor: Active Biotech AB

Conditions Prostate Cancer

Interventions Placebo tasquinimod

Updated 9 times since 2017 Last updated: Oct 2, 2015 Started: Mar 31, 2011 Primary completion: Feb 28, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Prostate Cancer and is currently completed. Active Biotech AB leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Nov 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Active Biotech AB

Data source: Active Biotech AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcorcón, Spain , Amsterdam, Netherlands , Angers, France , Arequipa, Peru , Athens, Greece , Atlanta, United States , Baia Mare, Romania , Bala-Cynwyd, United States , Baltimore, United States , Barcelona, Spain and 194 more locations